EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A Rare Case of Suspected Immune‐Related Encephalopathy Following Pembrolizumab Plus Lenvatinib Therapy for Renal Cell Carcinoma

Yuina Nagao iD, Kyotaro Fukuta iD, Yuichiro Atagi iD, Keisuke Ozaki, Takeshi Nakashima, Kenta Sato, Ryoichi Nakanishi, Hirofumi Izaki, Junya Furukawa iD

IJU Case Reports · 2026-07 · 9 (4)

DOI: 10.1002/iju5.70227 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IJU Case Reports, online erschienen am 12.07.2026. Verfasst von Yuina Nagao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology Tokushima Prefectural Central Hospital Tokushima Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Immune‐related encephalopathy is a rare neurological adverse event associated with immune checkpoint inhibitors. Neuroimaging and cerebrospinal fluid findings are often unremarkable, making the diagnosis challenging. Case Presentation A 70‐year‐old man with advanced clear cell renal cell carcinoma (RCC) was considered unresectable because of suspected adjacent organ invasion and high surgical risk. Therefore, pembrolizumab plus lenvatinib therapy was initiated, but 6 days later, he developed confusion, speech difficulty, and gait disturbance. Blood tests, whole‐body computed tomography (CT), contrast‐enhanced brain CT, contrast‐enhanced brain magnetic resonance imaging (MRI), electroencephalography, and cerebrospinal fluid examination showed no significant abnormalities. After excluding other causes, grade 3 immune‐related encephalopathy was suspected. Pembrolizumab and Lenvatinib were discontinued and high‐dose corticosteroids were started, leading to subsequent neurological improvement without residual deficits.

Conclusion

Immune‐related encephalopathy may occur early after pembrolizumab therapy. Early recognition and prompt steroid treatment are essential for a favorable neurological recovery.

Schlagwörter

Stichwörter der Autor:innen

immune checkpoint inhibitorimmune‐related encephalopathylenvatinibpembrolizumabrenal cell carcinoma

Autor:innen und Institutionen

  • Department of Urology Tokushima Prefectural Central Hospital Tokushima Japan.
  • Department of Neurology Tokushima Prefectural Central Hospital Tokushima Japan.
  • Department of Urology Tokushima University Graduate School of Biomedical Sciences Tokushima Japan.

ORCID-Profile: Yuina Nagao, Kyotaro Fukuta, Yuichiro Atagi, Junya Furukawa

Zitieren

APA

Nagao, Y., Fukuta, K., Atagi, Y., Ozaki, K., Nakashima, T., Sato, K., Nakanishi, R., Izaki, H., & Furukawa, J. (2026). A Rare Case of Suspected Immune‐Related Encephalopathy Following Pembrolizumab Plus Lenvatinib Therapy for Renal Cell Carcinoma. IJU Case Reports, 9(4). https://doi.org/10.1002/iju5.70227

Vancouver

Nagao Y, Fukuta K, Atagi Y, Ozaki K, Nakashima T, Sato K, et al. A Rare Case of Suspected Immune‐Related Encephalopathy Following Pembrolizumab Plus Lenvatinib Therapy for Renal Cell Carcinoma. IJU Case Reports. 2026;9(4). doi:10.1002/iju5.70227

BibTeX
@article{Nagao2026,
  author = {Nagao, Yuina and Fukuta, Kyotaro and Atagi, Yuichiro and Ozaki, Keisuke and Nakashima, Takeshi and Sato, Kenta and Nakanishi, Ryoichi and Izaki, Hirofumi and Furukawa, Junya},
  title = {A Rare Case of Suspected Immune‐Related Encephalopathy Following Pembrolizumab Plus Lenvatinib Therapy for Renal Cell Carcinoma},
  journal = {IJU Case Reports},
  year = {2026},
  volume = {9},
  number = {4},
  doi = {10.1002/iju5.70227}
}
Kostenlos starten →